Scarcity Breeds Strategy: How Biotech Companies Are Navigating the 2024–2025 Funding Crunch
The past two years have been a sobering period for the biotechnology industry. After the record-breaking highs of 2020 and 2021, the market has shifted dramatically. Investor sentiment has cooled, initial public offering (IPO) windows remain narrow, and early-stage fundraising has become markedly more difficult. In this new landscape, survival often depends not on who […]
From Clinical Trials to Unbroken: Sushmitha’s Journey of Leadership and Resilience
At Confidence Pharmaceutical Research, we know that the strength of our work comes from the people behind it. This month, we’re shining a spotlight on one of our Clinical Project Managers, Sushmitha Madhukar, whose career path in clinical research and recent journey as an author remind us how perseverance can shape both science and life. […]
Meet Vassily Gnedovsky, Director of Feasibility and Analytics at Confidence Pharmaceutical Research
At Confidence Pharmaceutical Research, delivering smarter, faster, and more reliable feasibility assessments is critical to ensuring clinical trial success. Vassily Gnedovsky, our Director of Feasibility and Analytics, brings nearly two decades of global experience to this mission—leading a team dedicated to designing robust strategies that guide country and site selection with precision and insight. With […]
Patient Enrollment and Retention in Rare Disease Studies
Clinical development in rare and orphan indications is often defined by urgency, unmet need, and an extraordinary level of complexity. While scientific innovation continues to drive therapeutic breakthroughs, many rare disease studies struggle to meet one fundamental milestone: patient enrollment and retention. At Confidence Pharmaceutical Research, we’ve supported trials in more than a dozen […]
Scarcity Breeds Strategy: How Biotech Companies Are Navigating the 2024–2025 Funding Crunch
The past two years have been a sobering period for the biotechnology industry. After the record-breaking highs of 2020 and 2021, the market has shifted dramatically. Investor sentiment has cooled, initial public offering (IPO) windows remain narrow, and early-stage fundraising has become markedly more difficult. In this new landscape, survival often depends not on who […]